Astrazeneca's Baxdrostat reduces BP in patients with uncontrolled hypertension in clinical trials
Positive full results from the BaxHTN Phase III trial showed AstraZeneca baxdrostat, demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses 2mg and 1mg compared with placebo at 12 weeks. Results were seen in patients with hard-to-control uncontrolled and resistant hypertension who received baxdrostat or placebo on top of standard of care.
